BRONKhIAL'NAYa ASTMA I KhRONIChESKAYa OBSTRUKTIVNAYa BOLEZN' LEGKIKh - DVE BOLEZNI ODNOGO BOL'NOGO. SOVREMENNYE PODKhODY K DIAGNOSTIKE I LEChENIYu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The combination of asthma and chronic obstructive pulmonary disease (COPD) is defined as «overlap»-syndrome and is characterized by incomplete reversibility of the limitation of respiratory flow in combination with a positive test for reversibility of bronchial obstruction. In patients suffering from «Asthma-COPD» comorbidity, progression of respiratory failure, reduction of effectiveness of previously effective inhaled glucocorticoids (IGC), reduction of exercise tolerance and quality of life are observed. Regardless of the severity of bronchial asthma, in patients with «Asthma-COPD» phenotype, the appointment of a combination of IGC and long-acting β2-agonists (LABA) is required as background therapy. In severe COPD with frequent symptoms, patients with «overlap»- syndrome need for «triple» background therapy, including IGC + LABA and long-acting anticholinergics.

Full Text

Restricted Access

References

  1. Глобальная стратегия лечения и профилактики бронхиальной астмы (пересмотр 2011 г.). Пер. с англ. под ред. А.С. Белевского. М., 2012. 108 с., ил.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2013. www.goldcopd.org/
  3. Биличенко Т.Н., Чучалин А.Г., Сон И.М. Основные итоги развития специализированной медицинской помощи больным пульмонологического профиля на территории Российской Федерации за период 2004-2010 гг. Пульмонология 2012: 3; 5-16.
  4. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59(5): 469-78.
  5. Емельянов А.В., Федосеев Г.Б., Сергеева Г.Р. и др. Распространенность бронхиальной астмы и аллергического ринита среди взрослого населения Санкт-Петербурга. Аллергология. 2002; 2: 10-15.
  6. Лещенко И.В. Распространенность бронхиальной астмы в Свердловской области. Пульмонология. 2001; 2: 50-55.
  7. Чучалин А.Г., Черняк Б.А., Буйнова С.Н., Тяренкова С.В. Распространенность и клинико-аллергологическая характеристика бронхиальной астмы в Восточной Сибири. Пульмонология. 1999; 1: 42-49.
  8. Green R.H., Brightling C.E., Woltmann G., et al. Analysis of induced sputum in adult with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002; 57: 875-79.
  9. Sorkness R., Bleecker E., Busse W., et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 2008; 104: 94-03.
  10. Dima E., Rovina N., Gerassimou C., et al. Pulmonary function tests, sputum indication, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 287-96.
  11. Hardin M., Silverman E.K., Barr R.G., et al. The clinical features of the overlap between COPD and asthma. Respir. Res. 2011; 12: 127.
  12. Sherrill D., Guerra S., Bodadilla A., Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur. Respir. J. 2003; 21(1): 95-00.
  13. Cazzola M., Puxeddu E., Bettoncelly G. et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir. Med. 2011; 105(3): 386-91.
  14. Soriano J.B., Davis K.J., Coleman B., et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003; 124: 474-81.
  15. O'Donnell D.E., Aaron S., Bourbeau J., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can. Respir. J. 2007; 14(Suppl. B): 5B-32B.
  16. Nagai A, Aizawa H, Aoshiba K, et al. Guidelines for the diagnosis and treatment of COPD. 3rd Edn. Tokyo, Japanese Respiratory Society, 2009.
  17. Brightling C.E., McKenna S., Hardagon B., et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005; 60: 193-98.
  18. Leigh R., Pizzichini M.M.M., Morris M.M., et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964-71.
  19. De Marco R., Accordini S., Cerveri I., et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175: 32-9.
  20. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009; 64: 728-35.
  21. Miravitlles M. The overlap syndrome between asthma and COPD: implications for management. Hot Topics Respir. Med. 2011; 16: 15-20.
  22. Hardin M., Silverman E.K., Barr R.G., et al. The clinical features of the overlap between COPD and asthma. Respir. Res. 2011; 12: 127.
  23. Miravitlles M., Andreu I., Romero Y., et al. Difficulties in differential diagnosis of COPD and asthma in primary care. Br. J. Gen. Pract. 2012; 62: e68-e75.
  24. Miravitlles M., Soler-Cataluna J.J., Calle M., et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch. Bronconeumol. 2012; 48(7): 247-57.
  25. Bafadhel M., McKenna S., Terry S., et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662-71.
  26. Hurst J. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 184: 625-26.
  27. Papi A., Romagnoli M., Baraldo S., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1773-77.
  28. Siva R., Green R.H., Brightling C.E., et al. Eosinophilic airway inflammation and exacerbation of COPD: a randomized controlled trial. Eur. Respir. J. 2007; 29: 906-13.
  29. Bafadhel M., McKenna S., Terry S., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. A randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2012; 186: 48-55.
  30. Williamson P.A., Menzies D., Clearie K.L., et al. Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur. Respir. J. 2011; 37: 206-09.
  31. Welte T., Miravitlles M., Hernandez P., et al. Efficacy and tolerability of budesonide / formoterol added to tiotropium in patients with COPD. Am. L. Respir. Crit. Care Med. 2009; 180: 741-50.
  32. Van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with COPD: the COPE study. Am. L. Respir. Crit. Care Med. 2002; 166: 1358-63.
  33. Wouters E.F., Postma D.S., Fokkens B., et al. COSMIC (COPD, Seretide: a Multi-Center Intervention, Characterization) Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained discase deterioration: a randomized controlled trial. Thorax. 2005; 60: 480-87.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media